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Abstract: The marine environment represents a relatively untapped source of functional 
ingredients  that  can  be  applied  to  various  aspects  of  food  processing,  storage,  and 
fortification. Moreover, numerous marine-based compounds have been identified as having 
diverse  biological  activities,  with  some  reported  to  interfere  with  the  pathogenesis  of 
diseases. Bioactive peptides isolated from fish protein hydrolysates as well as algal fucans, 
galactans  and  alginates  have  been  shown  to  possess  anticoagulant,  anticancer  and 
hypocholesterolemic  activities. Additionally, fish oils and marine bacteria are excellent 
sources  of  omega-3  fatty  acids,  while  crustaceans  and  seaweeds  contain  powerful 
antioxidants such as carotenoids and phenolic compounds. On the basis of their bioactive 
properties,  this  review  focuses  on  the  potential  use  of  marine-derived  compounds  as 
functional food ingredients for health maintenance and the prevention of chronic diseases. 
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1. Introduction 
Increasing  knowledge  regarding the  impact of diet on human  health along with state-of-the-art 
technologies has led to significant nutritional discoveries, product innovations, and mass production on 
an unprecedented scale [1]. In particular, naturally occurring bioactive extracts or single compounds 
thereof, that are believed to benefit human health, have spawned an important and dynamic new area 
of research resulting in substantial advances in nutritional knowledge. There is also growing awareness 
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that dietary source and form of food may affect overall health. Suitably, the role of food as an agent for 
improving health has been recognised, initiating the development of new classes of food, known as 
functional foods [2]. 
The concept of functional foods is to improve the general conditions of the body and decrease the 
risk of illness and disease [3]. That is to say, bioactive compounds present as natural constituents or as 
fortificants in food having the potential to provide health benefits beyond the basic nutritional value of 
the product. Marine-derived nutrients and other marine bioactive components have excellent potential 
as  functional  food  ingredients  as  they  possess  advantageous  physiological  effects,  with  medicinal 
characteristics and added health benefits such as anticancer or anti-inflammatory activity. 
The  marine  world,  due  to  its  phenomenal  biodiversity,  is  a  rich  natural  resource  of  many 
biologically  active  compounds  such  as  polyunsaturated  fatty  acids  (PUFAs),  sterols,  proteins, 
polysaccharides, antioxidants and pigments. Many marine organisms live in complex habitats exposed 
to  extreme  conditions  and,  in  adapting  to  new  environmental  surroundings,  they  produce  a  wide 
variety  of  secondary  (biologically  active)  metabolites  which  cannot  be  found  in  other  organisms. 
Moreover,  considering  its  great  taxonomic  diversity,  investigations  related  to  the  search  of  new 
bioactive compounds from the marine environment can be seen as an almost unlimited field [4,5]. 
Marine-based bioactive food ingredients can be derived from a vast array of sources, including 
marine plants, microorganisms, and sponges, all of which contain their own unique set of biomolecules 
[4]. However, proving that these naturally occurring bioactive substances have a defined health benefit 
poses a dilemma in nutritional research as investigating preventive activity can be difficult when effect 
is only moderate. This means that the effect of the compounds on the human body may be very small 
over  relatively  short  periods  but  could  contribute  significantly  to  health  when  they  are  consumed 
throughout  life  as  part  of  the  daily  diet  [1].  Therefore,  to  facilitate  discussion  of  this  issue,  the 
following review examines the existing scientific knowledge which demonstrates the suitability of 
marine-derived bioactive compounds as functional food ingredients for the prevention and treatment of 
chronic diseases. 
2. Sources of Marine Functional Food Ingredients 
2.1. Macroalgae 
Marine  algae  are  simple  chlorophyll  containing  organisms  composed  of  one  cell  or  grouped 
together in  colonies or as organisms  with many cells, sometimes  collaborating together as simple 
tissues. These unicellular or multicellular vegetative organisms do not have true roots or stems and 
vary greatly in size and morphology—from organisms 3–10 m in length to giant kelps up to 70 m 
long and growing up to 50 cm per day. Correspondingly, algae can be classified into two major groups 
according to their size: macroalgae or microalgae [6,7]. 
Macroalgae are more commonly known as seaweeds and several characteristics are used to classify 
them including the nature of their chlorophyll, their cell wall chemistry, and the presence or absence of 
flagella.  However,  the  feature most commonly  employed in algal classification is the presence  of 
specific pigments, other than chlorophyll, which clearly identify macroalgae as belonging to one of 
three algal divisions. In accordance with this criterion, macroalgae can be classified as brown algae Mar. Drugs 2011, 9                        
 
 
1058 
(Phaeophyceae), red algae (Rhodophyceae), or green algae (Chlorophyceae). The presence of these 
different phytopigments in algae is related to their sea habitat because not all macroalgae need the 
same light intensity to perform photosynthesis. Thus, green macroalgae, which are able to absorb large 
amounts of light energy, abound in coastal waters, while red and brown macroalgae prevail at greater 
depths where penetration of sunlight is limited [6]. 
Macroalgae  are  a  source  of  biologically  active  phytochemicals,  which  include  carotenoids, 
phycobilins,  fatty  acids,  polysaccharides,  vitamins,  sterols,  tocopherol  and  phycocyanins  among 
others. Many of these compounds are known to possess biological activity and hence have potential 
beneficial  use  in  healthcare  [8].  However,  the  chemical  and  nutritional  composition  of  seaweeds 
depends  on  many  factors,  including  species,  geographical  origin  or  area  of  cultivation,  seasonal, 
environmental,  and  physiological  variations,  time  of  harvest,  water  temperature,  and  processing 
methods [6,9–11]. For  example, a seasonal  variation of protein  content of  Palmaria palmata  was 
observed, with maximum values (approximately 21%) occurring during the winter-spring period and 
lower levels (12%) during the summer-early autumn period [12]. 
2.1.1. Proteins, Peptides and Amino Acids 
The protein content of macroalgae varies greatly from phylum to phylum [9]. Generally, the protein 
fraction of brown seaweeds is low (3–15% of dry weight) compared with that of the green or red 
seaweeds (10–47% of dry weight) [10]. The protein in macroalgae contains all essential amino acids, 
however, variations in their concentrations are known to occur [12]. Leucine, valine, and methionine 
are abundant essential amino acids of Palmaria palmata and their average levels are close to those 
generally  reported  for  ovalbumin.  On  the  other  hand,  isoleucine  and  threonine  concentrations  are 
similar to those recorded for legume proteins [6]. Leucine, phenylalanine and valine are the major 
essential amino acids of Ulva rigida, while levels of histidine, which is an essential amino acid in 
children, are similar to those found in legumes and eggs [13]. 
Recently, much attention has been paid to unraveling the structural, compositional and sequential 
properties of bioactive peptides. Marine bioactive peptides may be produced by one of three methods; 
solvent  extraction,  enzymatic  hydrolysis  or  microbial  fermentation  of  marine  proteins.  However, 
particularly in food and pharmaceutical industries, the enzymatic hydrolysis method is preferred on 
account of lack of residual organic solvents or toxic chemicals in the products. Bioactive peptides 
usually contain 3–20 amino acid residues and their activities are based on their amino acid composition 
and sequence [14,15]. These peptides are reported to be involved in various biological functions such 
as  antihypertension,  immunomodulatory,  antithrombotic,  antioxidant,  anticancer  and  antimicrobial 
activities, in addition to nutrient utilisation [15,16]. 
Among the algal proteins, it is worth noting the occurrence of protein-pigment complexes called 
phycobiliproteins, some of which are currently used as fluorescent markers in the fields of clinical 
diagnosis and biotechnological applications [17,18]. Recent studies have shown that phycobiliproteins, 
which generally make up 1–10% of dry weight of algal biomass, impart antioxidant properties which 
could  be  beneficial  in  the  prevention  or  treatment  of  several  diseases  [17].  Moreover,  in  some 
countries, phycobiliproteins are utilised as natural food colourings in products such as chewing gums, 
dairy products, jellies and ice sherbets [4]. Mar. Drugs 2011, 9                        
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Of note, the in vivo digestibility of algal proteins is poorly described, and available studies about 
their assimilation by humans have not provided conclusive results. Nonetheless, several studies have 
described a high rate of algal protein degradation in vitro by proteolytic enzymes such as pepsin, 
pancreatin  and  pronase.  For  instance,  the  in  vitro  digestibility  of  proteins  from  the  red  seaweed 
Porphyra tenera is approximately 70%. There is a possibility, however, that the high phenolic content 
of some algae may limit protein availability in vivo [9]. 
2.1.2. Fatty Acids 
The lipid content of macroalgae represents only 1–5%, thus its contribution as a food energy source 
appears to be low [17]. However, PUFAs account for almost half of this lipid fraction, with much of it 
occurring in the form of omega-3 (n-3) and omega-6 (n-6) fatty acids such as eicosapentanoic acid 
(EPA)  and  arachidonic  acid  (AA)  [19].  PUFAs  regulate  a  wide  range  of  functions  in  the  body 
including blood pressure, blood clotting, and correct development and functioning of the brain and 
nervous systems [20]. Furthermore, PUFAs have a role in regulating inflammatory responses through 
the production of inflammatory mediators termed eicosanoids [21]. 
The n-3 to n-6 ratio of macroalgae is closely matched which may add to their efficacy as a dietary 
supplement or as part of a balanced diet [22]. Moreover, they contain many essential fatty acids. Red 
and brown algae, for instance, are particularly rich in the n-3 fatty acids, EPA and -linolenic acid, and 
the n-6 fatty acids, AA and linoleic acid, along with relatively high levels of oleic and palmitic acids 
[11].  In  contrast,  green  seaweeds,  like  Ulva  pertusa,  are  characterised  by  the  presence  of 
hexadecatetraenoic (n-3), oleic and palmitic acids [23]. The n-3 fatty acid, octadecatetraenoic acid, is 
abundant in Laminaria sp. and Undaria pinnatifida while hexadecatetraenoic acid is prominent in  
Ulva sp. [6,24]. 
In addition to fatty acids, the unsaponifiable fraction of macroalgae contains carotenoids (such as  
-carotene,  lutein  and  violaxanthin  in  red  and  green  seaweeds,  fucoxanthin  in  brown  seaweeds), 
tocopherols, sterols (such as fucosterol in brown seaweeds) and terpenoids [25–28]. 
2.1.3. Polysaccharides 
Although algal carbohydrate content is relatively high, macroalgae cannot be considered a potential 
energy rich food as digestibility of these carbohydrates is low [6]. Moreover, the carbohydrate type 
varies greatly between algae species. Typical polysaccharides in red algae varieties consist of floridean 
starch, cellulose, xylan and mannan, and the water soluble fibre fraction is formed by sulfur containing 
galactans  such  as  agar  and  carrageenan.  Standard  polysaccharides  in  brown  algae  are  fucoidan, 
laminaran,  cellulose,  alginates  and  mannitol  whilst  the  fibres  are  mainly  cellulose  and  insoluble 
alginates. Most of these polysaccharides are not digestible by the human gastrointestinal tract and, 
therefore, can be regarded as dietary fibres [11]. The total dietary fibre content of seaweeds ranges 
from  29.3–62.3  g/100  g  [11,19,29],  and  so  is  higher  than  the  fibre  content  of  most  fruits  and 
vegetables. Human consumption of algal fibre has been proven to be health promoting and its benefits 
are well documented [13,30,31]. 
Storage  polysaccharides,  such  as  agar,  carrageenans  and  alginates,  are  the  most  commercially 
exploited  components  in  seaweeds.  These  storage  polysaccharides  exhibit  textural  and  stabilizing Mar. Drugs 2011, 9                        
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properties [19]; thus they are used in food applications such as thickening aqueous solutions, forming 
gels, forming water soluble films and stabilizing products such as ice-cream [4]. 
Fucoidans are a complex series of sulfated polysaccharides found widely in the cell walls of brown 
macroalgae.  Fucoidans  are  reported  to  display  numerous  physiological  and  biological  properties, 
including  anticoagulant,  antiviral,  antithrombotic,  antitumor  and  antioxidant  activities,  as  well  as 
having  an  effect  on  the  inflammatory  and  immune  systems  [32,33].  In  addition,  the  therapeutic 
potential of fucoidans increases with their degree of sulfation and they can be easily extracted using 
either hot water or an acid solution [32]. Another sulfated polysaccharide, porphyran, makes up the 
main components of the red macroalga, Porphyra [30]. This polysaccharide has reported uses as a 
gelling agent, a nutritional supplement and as an antioxidant [34]. Alternatively, laminarin, the second 
major storage  glucan in brown algae, has been identified as a modulator of intestinal metabolism 
through its effects on mucus composition, intestinal pH and short chain fatty acid production [34–36]. 
Another  group  of  carbohydrate  derivatives,  oligosaccharides,  are  commonly  defined  as 
carbohydrate  molecules  with  a  low  degree  of  polymerisation.  Oligosaccharides  can  be  produced 
naturally  or  may  be  derived  from  algal  polysaccharides  after  chemical,  physical  or  biochemical 
degradations.  To  date,  numerous  oligosaccharides  with  immunostimulation  activities  as  well  as 
antioxidant  and  antitumor  properties  have  been  characterised.  Moreover,  oligosaccharides  can  be 
beneficial to health when they are added to the diet to enhance the growth of prebiotic bacteria. In this 
case, oligomers that resist the digestive process are used as a specific substrate for the growth of health 
beneficial  bacteria  [37].  For  instance,  xylo-oligosaccharides  and  fructo-oligosaccharides  are  
non-digestible oligomers that cannot be absorbed in the gastrointestinal tract. Hence, they are intact in 
the large bowel and are used as a preferential substrate by anaerobic bacteria such as bifidobacteria and 
lactobacilli  [38,39].  Interestingly,  no  specific  conformation  is  correlated  to  the  non-digestible 
oligosaccharide’s  biological  activity,  whereas  the  immunostimulating,  antioxidant,  antiangiogenic 
and antithrombotic  activities  of  poly/oligosaccharides  molecules  are  determined  by  glycan  
conformation [37]. 
While algal polysaccharides have yet to be exploited in the food industry, the fact that they are easy 
to isolate and have numerous health benefits gives them the potential to serve as valuable bioactive 
ingredients in functional foods [4]. 
2.1.4. Vitamins, Minerals and Antioxidants 
One of the principal nutritive characteristics of seaweeds is their high antioxidant content (Table 1). 
In addition, vitamin B12 is found in red macroalgae (e.g., Palmaria   longat and Porphyra tenera) and 
in  certain  green  seaweeds  [9].  Red  and  brown  algae  contain  high  levels  of  folic  acid  and  folate 
derivatives  including  5-metil-tetrahydro-folate,  5-formyl-tetrahydro-folate  and  tetrahydro-folate. 
Indeed, amounts as high as 150 g folic acid per 100 g of dry Undaria pinnatifida algae have been 
detected [40]. As well as seasonal, environmental and physiological variations, vitamin content also 
depends on the type of seaweed processing. For example, the content of -tocopherol in Himanthalia 
  longate dehydrated (33.3 g/g dry weight) was considerably higher than in canned Himanthalia 
  longate (12 g/g dry weight) [41]. Mar. Drugs 2011, 9                        
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Table 1. Algal sources of dietary antioxidants. 
Antioxidant  Algal species  Reported levels (μg/g dry wt)  Reference 
Vitamin C  Ulva sp.  94.20–1250  [13,19] 
Monostroma undulatum  1590–4550  [6] 
Undaria pinnatifida  1847.38  [19] 
Ascophyllum nodosum  81.75  [19] 
Laminaria digitata  355.25  [19] 
Porphyra umbilicalis  1610.63  [19] 
Palmaria palmata  690  [19] 
Thalassiosira pseudonana  1100  [42] 
Chaetoceros muelleri  16000  [42] 
Gracilaria changgi  285  [43] 
Vitamin E  Ulva rigida  19.70  [13] 
Ascophyllum nodosum  3.63  [19] 
Dunaliella tertiolecta  200–500  [44] 
Undaria pinnatifida  145–174  [19] 
Laminaria digitata  34.38  [19] 
Porphyra umbilicalis  14.25  [19] 
Palmaria palmata  162  [19] 
α-tocopherol  Porphyridium cruentum  55.2  [45] 
Laminaria ochroleuca  8.9 ±  2.1  [41] 
Saccorhiza polychides  5.7 ±  1.3  [41] 
Himanthalia elongata  12.0–33.3  [41] 
Tetraselmis suecica  190–1080  [44] 
γ-tocopherol  Porphyridium cruentum  51.3  [45] 
Carotenoids  Porphyridium cruentum  1020 ±  140  [46] 
α-carotene  Chlorella pyrenoidosa  4232.50  [47] 
Dunaliella salina  2410–2690  [48] 
β-carotene  Ascophyllum nodosum    [26] 
Chlorella pyrenoidosa  4314.3  [47] 
Chlorella vulgaris  80–500  [49,50] 
Chlorococcum    [51] 
Dunaliella salina  4950–138250  [48,52–54] 
Fucus serratus    [26] 
Fucus vesiculosus    [26] 
Gracilaria changgi  52 ±  4  [43] 
Haematococcus pluvialis  80 ±  30  [55,56] 
Laminaria digitata    [26] 
Laminaria saccharina    [26] 
Pelvetia canaliculata    [26] 
Phormidium sp.    [57] 
Porphyra tenera    [58] 
Synechocystis sp.  2040  [59] 
antheraxanthin  Dunaliella salina    [53] 
Laminaria digitata    [26] 
Laminaria saccharina    [26] Mar. Drugs 2011, 9                        
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Table 1. Cont. 
astaxanthin  Chlorella vulgaris    [60] 
Chlorococcum sp.    [51,61] 
Haematococcus pluvialis  up to 3%  [52,56,62] 
β-cryptoxanthin  Chlorella pyrenoidosa  334.9  [47] 
cantaxanthin  Chlorella vulgaris    [60] 
Chlorococcum    [51] 
echinenone  Phormidium sp.    [57] 
Synechocystis sp.  240  [59] 
fucoxanthin  Ascophyllum nodosum    [26] 
Fucus serratus    [26] 
Fucus vesiculosus    [26] 
Hijikia fusiformis    [27] 
Himanthalia elongata  820  [59] 
Laminaria digitata    [26] 
Laminaria saccharina    [26] 
Pelvetia canaliculata    [26] 
loroxanthin  Chlorella pyrenoidosa    [63] 
lutein  Chlorella protothecoides  4600  [64] 
Chlorella pyrenoidosa  1153009.70  [47,63] 
Chlorella vulgaris  2970–3830  [49,50] 
Chlorella zofingiensis  3400  [64] 
Chlorococcum    [51] 
Dunaliella salina  6550 ±  920  [48,53] 
Haematococcus pluvialis  270 ±  60  [55,56] 
Muriellopsis sp.  4300  [64] 
Phormidium sp.    [57] 
Porphyra tenera    [58] 
Scenedesmus almeriensis  4500  [64] 
myxoxanthophyll  Synechocystis sp.  580  [59] 
neoxanthin  Ascophyllum nodosum    [26] 
Chlorella pyrenoidosa  199.7  [47] 
Dunaliella salina    [53] 
Fucus serratus    [26] 
Fucus vesiculosus    [26] 
Haematococcus pluvialis  60 ±  20  [55,56] 
Laminaria digitata    [26] 
Laminaria saccharina    [26] 
Pelvetia canaliculata    [26] 
Phormidium sp.    [57] 
violaxanthin  Ascophyllum nodosum    [26] 
Chlorella pyrenoidosa  38.1  [47,63] 
Fucus serratus    [26] 
Fucus vesiculosus    [26] 
Haematococcus pluvialis  40 ±  20  [55] 
Himanthalia elongata  50  [59] 
Laminaria digitata    [26] Mar. Drugs 2011, 9                        
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  Laminaria saccharina    [26] 
Pelvetia canaliculata    [26] 
Phormidium sp.    [57] 
zeaxanthin  Ascophyllum nodosum    [26] 
Chlorella pyrenoidosa  2170.3  [47] 
Dunaliella salina  11270 ±  1580  [48,53] 
Fucus serratus    [26] 
Fucus vesiculosus    [26] 
Haematococcus pluvialis  30 ±  10  [55] 
Himanthalia elongata  130  [59] 
Laminaria digitata    [26] 
Laminaria saccharina    [26] 
Pelvetia canaliculata    [26] 
Synechocystis sp.  1640  [59] 
Chlorophylls  Dunaliella salina  26–3100  [53,65] 
Himanthalia elongata    [59] 
chlorophyll a  Chlorella pyrenoidosa    [63] 
Chlorella vulgaris  3320–9630  [49,50] 
Chlorococcum    [51] 
Phormidium sp.    [57] 
Porphyra tenera    [58] 
Porphyridium cruentum  2130 ±  1200  [46] 
Tetraselmis suecica  6040–27530  [44] 
chlorophyll b  Chlorella pyrenoidosa    [63] 
Chlorella vulgaris  2580–5770  [49,50] 
Chlorococcum    [51] 
Haematococcus pluvialis    [56] 
Porphyridium cruentum  380 ±  340  [46] 
pheophytin a  Chlorella vulgaris    [50] 
Porphyridium cruentum  3310 ±  1110  [46] 
pheophytin b  Chlorella vulgaris  2310–5640  [49,50] 
Porphyridium cruentum  30 ±  90  [46] 
Polyphenols  Fucus sp.  41400 ±  400  [6] 
Haematococcus pluvialis    [66] 
Laminaria sp.  7300 ±  100  [6] 
Porphyra sp.  5700 ±  100  [6] 
Spongiochloris spongiosa  5.65  [67] 
Undaria sp.  6600 ±  100  [6] 
Seaweeds also contain an incomparable wealth of minerals and trace elements which are attributed 
to their capacity to retain inorganic marine substances due to the characteristics of their cell surface 
polysaccharides [6,19,68]. The mineral fraction  of some seaweeds accounts for up to 36% of dry 
matter [17]. Many of these essential minerals accumulate in seaweeds at much higher levels than in 
terrestrial foodstuffs. For example, there is more iron in an 8 g serving of dry Palmaria palmata than Mar. Drugs 2011, 9                        
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in 100 g of raw sirloin steak [19]. All of the essential minerals and trace elements needed for human 
nutrition are present in seaweeds [68], and so it should be regarded as a valuable functional food. For 
instance, the brown algae, Undaria pinnatifida and Sargassum, and the red algae, Chondrus crispus 
and Gracilariopsis, can be used as food supplements to help meet the recommended daily intake of 
some minerals (Na, K, Ca, Mg) and trace elements (Fe, Zn, Mn, Cu) [68,69]. Moreover, analysis of the 
mineral composition of Ulva rigida revealed balanced contents of Na and K (15.9 and 15.6  g/kg 
respectively, ratio near to 1), which, from a nutritional point of view, is of interest as intake of diets 
with a high Na/K ratio have been related to incidence of hypertension [13]. Additionally, seaweeds are 
one of the most important vegetable sources of calcium. Calcium content may be as high as 7% of the 
dry  weight  in  macroalgae  and  up  to  25–34%  in  the  chalky  seaweed,  lithotamne.  Thus,  seaweed 
consumption may also be useful to those at risk of calcium deficiency, namely expectant mothers, 
adolescents and the elderly [17]. 
Other bioactive compounds are the photosynthetic pigments used by autotrophs to capture solar 
energy  for  photosynthesis  [4].  As  regards  macroalgae,  the  main  pigments  are  carotenoids  and 
chlorophylls  (Table 1). The carotenoid fucoxanthin has potential commercial value as it has been 
reported to be of use in treating obesity and reducing the risk of certain diseases, such as type 2 
diabetes through its ability to promote the expression of the uncoupling protein, UCP1 [70]. In the 
food industry, chlorophylls are mainly used as natural colorants in foods and beverages [4]. However, 
chlorophylls and their derivatives have been shown to possess some biological activity whereby they 
exhibit anticancer properties in their ability to bind carcinogenic hydrophobic compounds such as 
polycyclic aromatic hydrocarbons, heterocyclic amines and aflatoxin [71,72]. Phlorotannins, a group 
of polyphenolic compounds which have also been identified in several brown algal families, have been 
reported to possess strong antioxidant activity. However, at present, the extractable polyphenol levels 
from algae are lower than that of other phytochemicals [6,73,74]. 
The  nutritional  value  ascribed  to  macroalgae  along  with  their  non-animal  nature  makes  them 
particularly appropriate for use in the food industry. Seaweeds have enormous potential as components 
of fertilizers, in animal feed supplements, and as additives for human food. Hence, biotechnological 
advances regarding macroalgae cultivation has stimulated the development of seaweed aquaculture. At 
present, three genera, Laminaria, Undaria and Porphyra, constitute 93% of the algal mass cultivated 
for nutritional purposes [6]. 
2.2. Microalgae 
Microalgae are the most primitive and simply organised members of the plant kingdom, with the 
majority existing as small cells of about 3–20 m [4]. These algae are ubiquitous in nature and aquatic 
microalgae have been isolated in areas ranging from hot springs to glacial ice flows [75]. Microalgae 
are found in both benthic and littoral habitats and also throughout the ocean waters as phytoplankton. 
Phytoplankton  comprises  organisms  such  as  diatoms  (bacillariophyta),  dinoflagellates  (dinophyta), 
green  and  yellow-brown  flagellates  (chlorophyta;  prasinophyta;  prymnesiophyta,  cryptophyta, 
chrysophyta and rhaphidiophyta) and blue-green algae (cyanophyta). As photosynthetic organisms, 
this group plays a key role in the productivity of oceans and constitutes the basis of the marine food  
chain [7]. Mar. Drugs 2011, 9                        
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There are over 50,000 different species of microalgae of which only a few have been characterised 
[75]. This group of microorganisms is extremely diverse and represents a major untapped resource of 
valuable  bioactive  compounds  and  biochemicals  such  as  pigments,  antioxidants,  polysaccharides, 
sterols, fatty acids and vitamins [76]. 
2.2.1. Proteins, Peptides and Amino Acids 
The  high  protein  content  of  various  microalgal  species  and  their  amino  acid  pattern,  which 
compares favourably with that of other food proteins, is a good endorsement of microalgae as an 
alternative protein source [77,78]. Spirulina, for instance, is high in protein (60–70% depending on the 
strain) and, not only does this protein possess all of the essential amino acids, but these amino acids 
have  excellent  bioavailability  [52].  Furthermore,  the  industrial  scale  growth  of  the  microalga, 
Dunaliella, can turn out protein extract at about 100 times greater productivity than that reported in 
agriculture and 50 fold greater than in fish farming [4]. 
Proteins from marine sources show promise as functional ingredients in foods because they possess 
numerous important and unique properties such as film and foaming capacity, gel forming ability and 
antimicrobial activity [4]. In addition, purified peptides from Chlorella vulgaris have demonstrated 
significant protective effects against cellular damage [79]. With regard to one of the major proteins in 
Spirulina platensis and Porphyridium, phycobiliprotein, several therapeutic bioactivities have been 
described,  namely,  hepatoprotective,  anti-inflammatory,  immunomodulating,  antioxidant  and 
anticancer effects [52]. 
2.2.2. Fatty Acids 
The average lipid content of algal cells varies between 1 and 70% but can reach 90% of dry weight 
under certain conditions [80]. Algal lipids are composed of glycerol, sugars or bases  esterified  to 
saturated or unsaturated fatty acids. Among all the fatty acids in microalgae, some fatty acids of the  
n-3  and  n-6  families  are  of  particular  interest  [42].  According  to  Mendes  et  al.  [60],  the  main 
constituents  of  the  lipidic  fractions  of  Chlorella  vulgaris  are  oleic,  palmitic  and  linolenic  acids, 
accounting for 41, 22 and 9% of the total amount, respectively. Additionally, palmitic, linolenic and 
oleic acids account for more than 85% of the total fatty acid content of Dunaliella salina [81], while 
the  green  microalga,  Haematococcus,  has  been  shown  to  contain  short  chain  fatty  acids  with 
antimicrobial activity [66]. 
Higher plants and animals lack the requisite enzymes to synthesize PUFAs of more than 18 carbons 
and so have to obtain them from their food. Fish and fish oil are the common sources of long chain 
PUFAs but safety issues have been raised because of the possible accumulation of toxins in fish. 
Moreover, the application of fish oil as a food additive is limited due to problems associated with its 
typical fishy smell, unpleasant taste and poor oxidative stability [78]. Consequently, long chain PUFAs 
are commercially produced via microalgae cultivation for incorporation into infant milk formulations 
and for use as dietary supplements and food additives [78]. Maximum n-3 fatty acid production can 
also be induced by altering the growth conditions of microalgae. For instance, under optimal culture 
conditions, Chlorella minutissima can produce an EPA content of up to 45% of its total fatty acid 
content [4]. Mar. Drugs 2011, 9                        
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Microalgae such as Porphyridium, which shows a relatively low lipid content, contains significant 
amounts  of  several  major  fatty  acids  such  as  palmitic  acid,  AA,  EPA  and  linoleic  acid  [46,52]. 
Spirulina provides an interesting source of γ-linolenic acid (20–25% of the total lipid fraction), which 
is  a  precursor  of  prostaglandins,  leukotrienes  and  thromboxans  involved  in  the  modulation  of 
immunological,  inflammatory  and  cardiovascular  responses  [17].  This  microalga  is  also  a  natural 
source  of  active  fatty  acids such  as lauric,  palmitic and oleic acids [82], with the n-3  fatty  acid, 
docosahexaenoic acid (DHA), accounting for up to 9.1% of the total fatty acids content. Spirulina has 
been found to contain sterols, including clionasterol which has been shown to increase the production 
of plaminogen-activating factor in vascular endothelial cells [76]. 
2.2.3. Polysaccharides 
Carbohydrates  in  microalgae  can  be  found  in  the  form  of  starch,  glucose,  sugars  and  other 
polysaccharides. Their overall digestibility is high, which is why there is no limitation to using dried 
whole  microalgae  in  foods  or  feeds  [78].  Moreover,  the  biological  activities  of  some  microalgal 
species  have  been  associated  with  polysaccharides.  Polysaccharide  complexes  from  Chlorella 
pyrenoidosa, and possibly Chlorella ellipsoidea, contain glucose and any combination of galactose, 
rhamnose, mannose, arabinose, N-acetylglucosamide and N-acetylgalactosamine. These complexes are 
believed  to  have  immunostimulating  properties,  specifically  immune  stimulatory  activity  and  can 
inhibit the proliferation of Listeria monocytogenes and Candida albicans [76]. The most important 
substance in Chlorella is -1,3-glucan, which is an active immunostimulator, a free radical scavenger 
and a reducer of blood lipids. Chlorella can also be used as a food additive owing to the taste and 
flavour  adjusting  actions  of  its  colouring  agent  [78].  Also,  novel  polysaccharides  isolated  from 
Porphyridium and Nostac flegelliforme microalgae exhibited potent antiviral activity against herpes 
simplex virus (HSV-1 and 2) both in vitro and in vivo [83,84]. 
2.2.4. Antioxidants 
The nutritional and therapeutic relevance of dietary carotenoids is attributed to their ability to act as 
provitamin A; that is, they can be converted into vitamin A by the human body. Moreover, carotenoids 
play  a  protective  role  by  preventing  the  formation  of  reactive  oxygen  species  [85].  Microalgal 
production of carotenoids, such as -carotene and astaxanthin, is an attractive area of research as they 
are  valuable  bioactive  ingredients  that  can  present  at  relatively  high  concentrations  in  algal  cells  
(Table 1). Moreover, cultivated algae can be induced to produce even larger quantities of carotenoids 
by controlling certain environmental growth conditions. The strains of microalgae that are currently 
being investigated for use as natural producers of commercial carotenoids include Dunaliella salina, 
Sarcina maxima, Chlorella protothecoides, Chlorella vulgaris and Haematococcus pluvialis [4]. 
Dunaliella salina is the most suitable organism for the mass production of -carotene as it can 
produce-carotene up to 14% of its dry weight [80]. This microalga can also be cultivated easily and 
quickly when compared to plants and produces both cis and trans isomers of carotenoids for high 
bioavailability and bioefficacy [85,86]. -carotene is one of the leading food colorants in the world and 
has been applied to a range of food and beverage products to improve their appearance to consumers 
[87].  In  addition,  -carotene  has  strong  antioxidant  properties  which  help  to  mediate  the  harmful Mar. Drugs 2011, 9                        
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effects of free radicals implicated in numerous life-threatening diseases, including various forms of 
cancer,  coronary  heart  disease  (CHD),  premature  aging  and  arthritis.  The  antioxidant  qualities  of  
-carotene  can  also  assist  the  body  in  suppressing  the  effects  of  premature  aging  caused  by  
UV rays [28,86]. 
Microalgal-derived -carotene has been reported to be more biologically active than synthetically 
produced  -carotene and can  be marked  as a  ―natural‖  food additive  [4]. Natural -carotene also 
contains numerous carotenoids and essential nutrients that are not present in the synthetic form and can 
be consumed in larger quantities as the body tissues regulate its use [88]. Additionally it has been 
observed  that,  under  irradiance  stress,  Dunaliella  salina  can  accumulate  significant  amounts  of 
xanthophylls, particularly zeaxanthin, which possess unique biological properties with potential for 
disease prevention [53]. 
Haematococcus is another unicellular alga that can be used in both open and closed culture systems 
for the production of antioxidants, namely chlorophylls and carotenoids [4]. Under stress conditions, 
Haematococcus pluvialis has the ability to accumulate large quantities (1.5–3% of dry weight) of the 
high value carotenoid, astaxanthin [62]. Besides, the United States Food and Drug Administration for 
marketing has cleared Haematococcus pluvialis as a dietary supplement and it has also been approved 
in several European countries for human consumption [76]. With an antioxidant activity up to 10 times 
stronger than other carotenoids, astaxanthin provides protective activity against cancer, inflammation 
and UV light. The health benefits of astaxanthin along with its strong colouring properties make it a 
potential ingredient for use in the nutraceutical, cosmetics, food and feed industries [89]. 
Microalgae also represent a valuable source of nearly all essential vitamins (A, B1, B2, B6, B12, C, E, 
nicotinate, biotin, folic acid and pantothenic acid) and are generally rich in chlorophylls (Table 1) [78]. 
It has clearly been established that microalgae are a rich source of nutritious and biologically active 
compounds,  namely  carotenoids,  phycobilins,  fatty  acids,  polysaccharides,  vitamins  and  sterols. 
Nevertheless, not only is it their huge diversity that makes these microorganisms interesting, but also 
the possibility of growing them at different conditions and using them as natural reactors, leading to an 
enrichment of some bioactive compounds. However, prior to this, algal material must be analysed for 
the presence of toxic compounds. 
Despite  the  growing  promise  of  microalgae  as  a  source  of  food  ingredients,  the  industry  has 
developed with only varying amounts of success and its biotechnological potential remains to be fully 
exploited [4]. One such future application could be in the production of special lipids. The n-3 fatty 
acids found in the oils of certain cold water marine fish, which are believed to be capable of reducing 
the incidence of CHD, are likely to originate from the phytoplankton in food chain. Many of these 
phytoplankton species are found to be rich in reserves of oils containing various amounts of EPA and 
DHA [75]. Indeed, the oil obtained from the microalga Schizochytium sp. has been authorized by the 
United States to be used as a new food ingredient because of its high DHA (n-3) content and because it 
contains higher levels of squalene and phytosterols but three times less cholesterol than fish oil [6,78]. 
2.3. Byproducts of Processing 
Byproducts  of  processing  are  generated  when  the  fish/shellfish  is  gutted,  headed  and  further 
processed  either  onboard  fishing  vessels  or  in  processing  plants  on  shore  [90].  Production  of  Mar. Drugs 2011, 9                        
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marine-based food ingredients from these byproducts is a growing area of interest as it could help to 
reduce processing waste, thereby catering to ethical and environmental concerns over discards, and 
primarily, it could result in the development of valuable nutraceutical or functional food formulations 
[4]. According to Kelleher [91], discards from the world’s fisheries in 2005 exceeded 7 million tons, 
with only 50% of total catch being used for actual human consumption [92]. Fish heads, viscera, skin, 
tails, offal and blood, as well as seafood shells possess several compounds suitable for human health 
applications [93]. Studies have identified compounds from remaining fish muscle proteins, collagen 
and gelatin, fish oil, fish bone, internal organs, and shellfish and crustacean shells [94,95]. 
These bioactive compounds can be extracted and purified with various technologies leading to the 
preparation and isolation of bioactive peptides, oligosaccharides, fatty acids, enzymes, water soluble 
minerals and biopolymers for biotechnological and pharmaceutical applications [96]. 
2.3.1. Proteins, Peptides and Amino Acids 
Fish  muscle  proteins  derived  from  processing  byproducts  can  be  hydrolysed  enzymatically  to 
recover protein biomass otherwise discarded as processing waste. Bioactive peptides isolated from 
various  fish  protein  hydrolysates  have  shown  numerous  bioactivities  such  as  antihypertensive, 
antithrombotic [96–98], anticoagulant [99], immunomodulatory and antioxidative activities [99,100]. 
Moreover,  Jung  et  al.  [101]  reported  that  fish  peptides  are  also  capable  of  accelerating  calcium 
absorption. 
Some of the most prevalent marine proteins used in foods are collagen, gelatin and albumin, all of 
which can be extracted from fish and seafood byproducts [4]. Collagen and gelatin are unique proteins 
as they are rich in non-polar amino acids (above 80%) such as glycine, alanine, valine and proline [96]. 
Collagen is a connective tissue protein found in skin, bones, cartilage, and ligaments which can be 
extracted  from  fish  processing  byproducts  [4].  Collagen  derived  from  species  living  in  warmer 
environments (e.g., tuna) have higher contents of proline and hydroxyproline, so they present a higher 
melting point and superior thermal stability than those from fish that live in cooler environments (e.g., 
cod) [93]. Gelatin is a protein product formed by the partial hydrolysis of collagen. It has a unique gel 
forming ability [4] and is used as a food additive to increase the texture, the water holding capacity and 
stability  of  several food  products [92]. Traditionally,  gelatin has been  derived from  beef or pork; 
however, marine gelatin can also be extracted from the skins of flatfish, cold water fish species or 
alternative sources such as squid and octopus [4,102]. Gelatin possesses a characteristic melt-in-the-
mouth property, which makes it suitable to a wide range of applications in food and pharmaceutical 
industries; in particular, fish gelatin has a better release of aroma and shows a higher digestibility than 
animal gelatin [103]. 
Other  bioactive  proteins  that  can  be  obtained  from  marine  processing  include  albumin  and 
protamine. Albumin, has exhibited several properties that make it beneficial to human health, such as 
antioxidant and anticoagulatory activities and the ability to maintain microvascular integrity [104]. 
While it is typically derived from egg whites, albumin can also be isolated from mollusks, crustaceans 
and low fat fish [4]. Protamine is a simple peptide consisting largely of arginine residues that is found 
in the testicles of more than 50 fish species. Protamine is a promising antibacterial agent in food 
processing and preservation as it has the ability to prevent growth of Bacillus spores [92]. Also, major Mar. Drugs 2011, 9                        
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marine enzymes are produced as a result of fish and shellfish processing. These enzymes are valuable 
as food ingredients and in food processing due to their specificity, diverse properties, salt tolerance, 
and high activity at mild pH [4]. However, different opinions exist as to the cost and economy in 
extracting these enzymes as opposed to having them produced by microorganisms. 
2.3.2. Fatty Acids 
Better  utilization  of  marine  fish  processing  byproducts  could  be  achieved  by  converting  these 
materials into fish oil [96]. The liver of lean white fish such as cod species, the muscle of fatty fish 
(herring, mackerel, salmon) and offal generated from processing are all good sources of marine lipids 
[92,96]. The fat content of fish varies from 2–30% and is mainly composed of two types of PUFAs, 
EPA and DHA [96]. Compared to saturated fats, PUFAs in fish oil are readily digested for energy 
production [96] and are believed to be the main protective components of fish oil that act against 
certain types of diseases. 
Cod liver oil has long been used as a fish oil supplement as it contains high amounts of PUFAs, 
much of which is the n-3 fatty acid, EPA [105]. Although supplements are popular in Europe and 
Japan, a more attractive option for many in the food industry is to enrich everyday products like bread, 
egg, margarine etc. with n-3 long chain PUFAs [4]. However, the main factor limiting the application 
of these PUFAs in food products is their susceptibility to lipid oxidation, which can result in strong 
fishy odours and flavours [4,92]. 
2.3.3. Polysaccharides 
Chitin is ubiquitous in marine polysaccharides; it is one of the major structural components of 
crustacean  shells  and  shellfish wastes with  a structure similar to that of cellulose, and built  from  
n-acetyl-glucosamine  monomers  [106].  On  a  dry  weight  basis,  shrimp,  crab,  lobster,  prawn  and 
crayfish have been reported to contain between 14 and 35% chitin, while deproteinized dry shell waste 
of Antarctic krill contains approximately 40% crude chitin. As the insolubility of chitin hampers most 
of its applications, once isolated, chitin can be deacetylated to create chitosan, a large cationic polymer 
with numerous commercial applications in the food, pharmaceutical and waste treatment industries [4]. 
In  practice,  chitin  is  used  almost  exclusively  as  raw  material  for  production  of  chitosan, 
oligosaccharides and glucosamine [93]. There are a variety of food applications for chitin, chitosan and 
their derivatives, including use as antimicrobial agents, edible films, additives, nutraceuticals (e.g., 
increasing dietary fibre, reducing lipid absorption) and water purifiers [107]. 
Chito-oligosaccharides are chitosan derivatives that can be generated via chemical or enzymatic 
hydrolysis of chitosan. Recently, these oligosaccharides have been the subject of increased attention in 
terms of their pharmaceutical and medicinal applications, due to lack of toxicity, high solubility and 
their  positive  physiological  effects  such  as  angiotensin-I-converting  enzyme  (ACE)  inhibition, 
antioxidant,  antimicrobial,  anticancer,  immunostimulant,  hypocholesterolemic,  hypoglycemic  and 
anticoagulant properties [31]. Mar. Drugs 2011, 9                        
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2.3.4. Calcium and Astaxanthin 
Fish bone, which is separated after removal of muscle proteins on the frame, is a valuable source of 
calcium, which is an essential element for human health. As calcium is deficient in most regular diets, 
demand for calcium fortified products is growing continuously, and fish bone material is a useful 
source [108]. However, in order to incorporate fish bone into calcium fortified food it needs to be 
converted into an edible form by softening its structure [96]. 
Astaxanthin represents between 74 and 98% of the total pigments in shellfish. Due to these high 
contents,  crustacean  shells  can  not  only  be  used  for  recovery  of  chitin  but  also  for  recovery  of 
astaxanthin.  Owing  to  its  useful properties,  astaxanthin from natural sources is increasingly being 
marketed as a functional food ingredient with prices ranging between $3,000 and $12,000 per kg. The 
methods currently available for the extraction of astaxanthin from shell matrices employ different 
elements such as edible oils, hydrochloric acid and organic solvents. Also, a feasible technique for 
partial concentration of astaxanthin from crustacean shells is via lactic acid fermentation, which also 
has the advantage of protecting the biomass from bacterial decomposition. The silage formed contains 
insoluble chitin, a protein rich fraction, and a lipid rich fraction composed of astaxanthin, sterols, and 
vitamins A and E [93]. 
2.4. Other Benthic Species 
The  majority  of  bioactive  marine  molecules  have  been  isolated  from  benthic  species  such  as 
sponges,  bryozoans,  echinoderms,  polychaetes,  ascidians,  mollusks  and  cnidarians  [109].  These 
molecules  have  recognized  applications  against  cancer,  inflammation,  HIV-AIDS,  thrombotic 
disorders and infectious diseases [110]. In fact, more ascidian- and sponge-derived compounds are in 
clinical and preclinical trials than compounds from any other marine taxa [109]. 
An emerging source of new bioactive ingredients may result from the microbial diversity in the 
marine environment, particularly those microbes associated with marine plants and animals. Several 
studies  have  demonstrated  that  ―living  surfaces‖  represent  an  environment  rich  in  epibiotic 
microorganisms that produce bioactives [111]. Many of these marine microorganisms can be easily 
cultured and manipulated in bioreactors and, therefore, represent an excellent renewable source of 
biologically active compounds. Some deep sea bacteria have been found to contain large amounts of 
EPA and DHA, presumably to allow their membranes to be fluid and adaptive to extreme temperatures 
and pressures [4]. For example, Mortierella alpina can produce EPA as 15% of total extractable fatty 
acid at 12 ° C [112]. Moreover, extremophiles contain polysaccharides with a wide variety of chemical 
and physical properties that are often not present in or are variations of the more traditional, terrestrial 
plant-derived  polysaccharides.  One  strain  of  Alteromonas  has  been  found  to  produce  an  anionic 
exopolysaccharide with potential use as a thickening agent, while other Altermonas strains produced 
polymers with qualities such as unusual gelling properties, significant thickening ability, and high 
metal binding capacity [113]. In addition, halophiles such as Halobacterium mediterranei have been 
reported to contain exopolysaccharides with highly favourable rheological properties and resistance to 
high  salinities,  temperatures  and  pH  [4].  Other  promising  sources  of  functional  food  ingredients 
include a red coloured bacterium obtained from Puerto Rico which was found to excrete vitamin B and Mar. Drugs 2011, 9                        
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antibacterial substances into the sea water [75], while Dharmaraj et al. [114] confirmed the production 
of  food  grade  carotenoids  by  Streptomyces  microbes  isolated  from  the  marine  sponge  
Callyspongia diffusa. 
Lower invertebrates, such as sponges, represent a great diversity of lipid components, such as fatty 
acids, sterols, and other unsaponifiable compounds, as well as compounds such as bioactive terpenes, 
cyclic peptides, alkaloids, peroxides, and amino acid derivatives [115]. However, sponge mariculture 
has not yet proven to be very lucrative as little is known about how to replicate the sponge’s natural 
environment and life cycle. Also, the bioactive compounds of interest are often only produced in trace 
amounts [4,115]. 
Another  prospective  source  of  n-3  long  chain  PUFAs  is  the  class  of  algae-like  fungi  called 
phycomycetes. These marine fungi have been reported to produce significant levels of γ-linolenic acid, 
AA, EPA and DHA [4]. 
3. Potential to Reduce Prevalence of Chronic Diseases 
The increasing number of scientific papers published in the last two decades correlating diet and 
some  chronic  diseases  have  shown  the  extraordinary  possibilities  of  foods  to  support,  or  even  to 
improve, our health. As a consequence, there is now a huge interest among consumers and the food 
industry on products that can promote health and well-being [5]. The marine world represents a largely 
untapped reserve of bioactive ingredients and considerable potential exists for exploitation of these 
compounds as functional food ingredients (Table 2). Substances such as chitin, chitosan, n-3 oils, 
algae, carotenoids, vitamins and minerals, calcium in fish bone, bioactive peptides and fish protein 
hydrolysates provide a myriad of health benefits, including reduction of CHD, anticarinogenic and 
anti-inflammatory activities [4,8]. 
An  important  element  of  nutritional  discovery  is  the  molecular  target  or  pathway  selected  for 
modulation. Nutritional bioactives aiming at the prevention of diseases or slowing disease progression 
will  at  least  partly  overlap  with  those  targeted  by  the  pharmaceutical  industry  such  as  enzymes, 
receptors, or transcription factors. Additionally, elements that maintain cell homeostasis upstream of 
the final events that lead to the pathophysiological deteriorations may also be targeted by nutritional 
compounds [116]. In proving a defined health effect, however, the health promoting effect of these 
naturally occurring bioactive substances must be preventive, fundamentally distinguishing them from 
curative drugs [1]. 
Table 2. Potential marine functional food ingredients and their health benefits. 
Functional food 
ingredient 
Health benefit  Marine source  Reference 
Peptides  ACE inhibition  Fish frame, algae  [15,31,97,98] 
Anticoagulative  Fish frame  [15,99] 
Antidiabetic  Fish frame  [117] 
Antimicrobial  Marine invertebrates, fish  [15,118] 
Antioxidative  Algae protein waste, fish frame  [15,79,95] 
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Table 2. Cont. 
n-3 fatty acids  Anticarcinogenic  Fish  [119–122] 
Anti-inflammatory  Fish, mussels  [20,123] 
Cardioprotective  Fish  [124,125] 
Cognitive function  Fish  [126,127] 
Polysaccharides  Anticarcinogenic  Algae, crustaceans  
(chito-oligosaccharides) 
[94,128,129] 
Antioxidative  Algae, crustaceans  
(chito-oligosaccharides) 
[129,130] 
Antiviral  Algae  [83,129] 
Cardioprotective  Algae  [131–133] 
Carotenoids  Anticarcinogenic  Algae  [58,134] 
Antioxidative  Algae  [27,48] 
Anti-obesity  Algae  [70] 
Antidiabetic  Algae  [135] 
Chlorophyll  Anticarcinogenic  Algae  [58,71] 
Polyphenols  Antidiabetic  Algae  [136–138] 
Antioxidative  Brown algae  [73] 
3.1. Cancer 
Many potent natural products which display effective anticancer activities have been discovered in 
the  marine environment.  Indeed, since the  early 1990s, there  has been  a dramatic increase in the 
number of preclinical anticancer lead compounds from marine sources that have entered into human 
clinical trials [139,140]. One of these compounds, trabectidin (Yondelis
®), originally isolated from the 
Caribbean marine tunicate Ecteinascidia turbinate, has been approved for use as an anticancer agent in 
Europe  [141,142].  In  addition,  dehydrodidemnin  B  (aplidine),  a  compound  extracted  from  the 
Mediterranean marine tunicate, Aplidium albicans, has been shown to be a powerful antitumor agent 
with possible applications in treating prostate, gastric, breast and colon cancers [140,143]. 
Marine-derived anticancer molecules have varying modes of action. A cell culture study by Russo 
et al. [144] reported that two lichen metabolites, sphaerophorin and pannarin, prevented UV light and 
nitric oxide mediated plasmid DNA damage, and attenuated the growth of melanoma cells by, at least 
in part, triggering an apoptotic process. Moreover, a number of isolated marine sponge compounds are 
inhibitors  of  protein  kinase  C  (PKC)  e.g.,  BRS1,  isoaaptamine,  debromohymenialdisine.  PKC 
inhibitors have attracted much attention as there is evidence that too high levels of PKC enzyme are 
involved in the pathogenesis of arthritis and psoriasis, and in tumor development. PKC is believed to 
be the receptor protein of tumor promoting phorbol esters, and PKC inhibitors prevent binding of 
carcinosarcoma cells to the endothelium [145]. The cytoskeleton is also an interesting target for cancer 
therapy,  as  the  microtubules  and  microfilaments  are  involved  in  cellular  organisation  during  cell 
division. A number of extracts of marine sponges and ascidians are believed to inhibit the protein by 
binding  to  the  microtubule  binding  site,  ―locking  up‖  the  protein’s  motor  function,  and  thereby 
blocking  cell  division  [145–147].  Other  metabolites  can  inhibit  cell  division  by  disrupting  the 
polymerisation of actin [148,149], inhibition of cyclin-dependent kinase 4 [150,151], inhibition of Mar. Drugs 2011, 9                        
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protein synthesis [152,153] or by blocking topoisomerase II [154–156], the nuclear enzyme which 
makes transient DNA breaks that are required for replication [157]. 
In  contrast,  incubation  with  kahalalide  F,  a  cyclic  depsipeptide  from  the  herbivorous  marine 
mollusk, Elysia rufescens, quickly induced loss of mitochondrial membrane potential and lysosomal 
integrity, severe cytoplasmic swelling and vacuolisation, irregular clumping of chromatin within the 
cell nucleus, and finally, cell death in human cancer cells. These effects were independent of caspase 
activation and were not associated with DNA degradation or cell cycle block. Kahalalide F has shown 
to be effective against cell lines with strong multidrug resistance and against cell lines resistant to 
topoisomerase II inhibitors. In vivo models have also confirmed activity in various solid tumor models 
[158,159].  To  date,  copious  numbers  of  compounds  with  reported  anticancer  activities  have  been 
extracted  from  marine  organisms,  however,  for  some,  their  exact  effects  are  still  
unclear [140,142,145]. 
3.1.1. Algal Polysaccharides 
Wijesekara et al. [129] recently reported that algal sulfated polysaccharides have potent capacities 
for new anticancer product developments in the pharmaceutical as well as the food industries. Indeed, 
several  in  vivo  mouse  studies  have  demonstrated  the  antitumor  activity  of  marine-based 
polysaccharides  [94,160–164].  Moreover,  non-digestible  oligosaccharides,  which  are  found  in 
abundance in macroalgae, are known to improve gut microecology and in doing so may reduce the risk 
of  colon  cancer.  In  a  review  by  Mussatto  and  Mancilha  [38],  the  authors  state  that  intake  of 
transgalactosylated  disaccharides  reduces  the  faecal  pH  as  well  as  ammonia,  p-cresol  and  indole 
concentrations, with an increase in bifidobacteria and lactobacilli and a decrease in Bacteroidaceae 
populations. As these changes in faecal physiological parameters are believed to reduce the risk of 
cancer  development,  macroalgal  non-digestible  oligosaccharides  could  be  considered  as  potential 
anticarcinogenic food ingredients [34,38]. 
3.1.2. n-3 Polyunsaturated Fatty Acids 
While the cardioprotective effects of fish oil n-3 PUFAs are well established, their antitumoral 
effects are not widely acknowledged. However, promising data from experimental studies carried out 
in animals show that elevated supplies of EPA, DHA and/or fish oil diet supplementation generally 
inhibit  tumor  growth  and  metastases  occurrence  [121,122,165–167].  Using  a  mouse  model  of  
MDA-MB-231 human breast cancer cell metastasis to bone, research by Mandal et al. [120] found that 
a  fish  oil  diet  enriched  in  DHA  and  EPA  prevented  the  formation  of  osteolytic  lesions  in  bone, 
indicating suppression of cancer cell metastasis to bone. The study also revealed markedly reduced 
levels of CD44 mRNA and protein (associated with generation of cancer stem cells) in the tumors of 
mice fed fish oil diet compared to those fed the control diet. Furthermore, Brown and colleagues [168] 
provided in vitro evidence supporting epidemiological data that the dietary ratio of n-3:n-6 is crucial in 
determining the risk of metastatic disease in prostate cancer. Increasing the ratio of n-3 to n-6 PUFAs, 
in particular increasing the amount of EPA in the diet, can inhibit the metastatic process by blocking 
the production of prostaglandin E2 and thereby reducing the risk of aggressive disease. Mar. Drugs 2011, 9                        
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3.1.3. Carotenoids and Chlorophylls 
Being lipid soluble, carotenoids are absorbed with fats and circulate bound to different lipoproteins. 
The principal biological effects of carotenoids relate to their antioxidant properties, which form the 
basis  of  potential  protection  against  lipid  peroxidation,  atherogenesis,  DNA  oxidation,  and  cancer 
[169]. Carotenoids have been implicated in the inhibition of cancer cells in vitro [170–172], in animal 
models [173,174] and in humans, as important dietary phytonutrients having cancer preventive activity 
for lung, colon, breast and prostate cancer [175,176]. As regards marine-sourced carotenoids, Cha  
et al. [134] found that the carotenoid extract of Chlorella ellipsoidea exerted strong antiproliferative 
effects  on  human  colon  cancer  cells,  including  induction  of  apoptosis.  The  authors  suggest  that 
bioactive xanthophylls of C. ellipsoidea could be potential therapeutic agents in the prevention of 
human  cancers.  Several  studies  have  also  demonstrated  the  anticancer  activity  of  astaxanthin  in  
mammals [177–179]. 
The  cancer  preventative  effect  of  chlorophyll  derivatives  have  been  extensively  studied,  with 
particular  emphasis  on  their  in  vitro  antimutagenic  activity  against  numerous  dietary  and 
environmental mutagens [180–184]. In a study presented by Chernomorsky et al. [71], the authors 
conclude that food sources that yield chlorophyll derivatives may play a significant role in cancer 
prevention. They found that dietary chlorophyll derivatives exhibit antimutagenic effects and reduce 
tumor  cell  growth.  Indeed,  epidemiological  evidence  has  linked  diets  high  in  chlorophyll  with  a 
reduced risk of colon cancer in humans [185]. Antioxidant activity, mutagen trapping, modulation of 
detoxification pathways, and induction of apoptosis in cancer cells have been highlighted as possible 
modes of actions responsible for chlorophyll’s protective effects in vivo [186]. 
Neither  carotenoids  nor  chlorophylls  can  be  synthesized  by  animal  tissues  [187].  Thus,  these 
molecules  must  be  obtained  from  food  and,  as  previously  illustrated,  the  marine  environment 
represents an endless resource. Carotenoid and chlorophyll molecules can be extracted and used as 
natural colorants and antioxidants to restore the natural level of these molecules in food or to prepare 
fortified products. They can also be chemically modified before being incorporated into food products 
[187]. Overall, positive data from in vitro and animal studies have prompted an increased interest in 
the potential usefulness of carotenoids and chlorophylls as preventative agents for human populations 
at elevated risk of development of specific cancers [186]. 
3.2. Cardiovascular Disease 
Cardiovascular disease (CVD) is a class of diseases that affect the heart, blood vessels (arteries and 
veins) and blood circulation, and is one of the leading causes of mortality and morbidity worldwide. 
Examples  of  CVD  include  atherosclerosis,  CHD,  stroke,  heart  failure,  deep  vein  thrombosis  and 
peripheral arterial disease. In relation to marine bioactives, there is considerable evidence that these 
compounds can help to reduce the risk factors associated with CVD. Low density lipoprotein (LDL) 
cholesterol was significantly lower in rats fed a diet containing dried Ulva rigida [13], while Oben and 
colleagues  [188]  found  that  individuals  given  a  freshwater  algae  infusion  displayed  lower  total 
cholesterol,  LDL  cholesterol  and  triglyceride  levels,  and  higher  high  density  lipoprotein  (HDL) 
cholesterol values than those given a water placebo. Mar. Drugs 2011, 9                        
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3.2.1. Polysaccharides 
Numerous epidemiological studies have shown a strong correlation between high fibre diets and a 
lower  incidence  of  chronic  disorders  such  as  CVD  [189–193].  Soluble  fibre  forms  a  viscous 
indigestible mass in the gut and helps trap digestive enzymes, cholesterol, starch, glucose, and toxins 
which are then expelled through the faeces. The soluble fraction of fibres has a hypocholesterolemic 
effect, possibly due to augmented gastrointestinal content interfering with micelle formation and lipid 
absorption, or an increase and excretion of neutral sterols and biliary acids. Given that seaweed contain 
a large amount of soluble polysaccharides, they therefore have potential function as dietary fibre [194]. 
Additionally, several investigators have reported that water soluble fractions of seaweeds or isolated 
algal  polysaccharides  induce  hypocholesterolemic  and  antihypertensive  effects  in  experimental 
animals  [131,195,196].  Indeed,  sodium  alginate  and  fucoidan  were  found  to  decrease  serum 
cholesterol levels in vivo [132,133,197]. 
3.2.2. n-3 Polyunsaturated Fatty Acids 
The amount of fat in the diet and the type of fatty acids consumed can influence the likelihood of 
CVD and its risk factors [22]. The first recognition of the beneficial effect of fatty acids on CVD came 
from the observations on the longevity of Eskimos, which was later attributed to the high contents of 
fish-derived n-3 long chain fatty acids (e.g., EPA and DHA) in their diets [198–201]. Since then, the 
cardioprotective effects of fish oil n-3 PUFAs appear well determined. Numerous epidemiological and 
experimental studies have conclusively shown that diets rich in fish and fish oils are associated with a 
reduced risk of CVD [202–211]. The omega-3 index, a proposed biomarker for CVD risk, is the level 
of EPA and DHA in red blood cell membranes (expressed as a percent of total fatty acids), and an 
index of 8% or greater has been posed as a target for reducing CVD [212]. Research carried out by 
Lerman et al. [213] found that provision of 2–3 g/day of EPA and DHA for 12 weeks increased the 
omega-3  index  by  3.7  to  4.1  percentage  points  to  cardioprotective  levels.  Moreover,  fish  oil 
supplementation has been shown to be beneficial in controlling high blood pressure [214–216]. 
3.2.3. ACE-Inhibitory Peptides 
High blood pressure (hypertension) is one of the major independent risk factors for CVD [217]. 
ACE plays a crucial role in the regulation of blood pressure [15], and so ACE inhibition is considered 
to  be  a  useful  therapeutic  approach  in  the  treatment  of  hypertension.  Numerous  investigations  of 
marine-derived  peptides  have  revealed  potent  antihypertensive  and  ACE  inhibitory  activities  in 
hypertensive rats [218–221]. According to Lee et al. [222], a single oral administration of a peptide 
derived from tuna frame protein hydrolysate showed a strong suppressive effect on systolic blood 
pressure of spontaneously hypertensive rats and this antihypertensive activity was similar to that of 
captopril, a commercial antihypertensive drug. Therefore, due to their effectiveness in both prevention 
and treatment of hypertension, marine-derived bioactive peptides have prospective use as functional 
ingredients [15]. Mar. Drugs 2011, 9                        
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3.2.4. Astaxanthin 
Due to their antioxidant properties, carotenoids are believed to have therapeutic benefit in treating 
CVD [223,224]. In addition, astaxanthin, a carotenoid ubiquitous in the marine environment, exhibits 
anti-atherogenic effects. In a study involving hyperlipidemic rabbits, astaxanthin significantly reduced 
macrophage infiltration in lesions and lowered the occurrence of macrophage apoptosis and plaque 
ruptures  [225].  Indeed,  results  of  human  intervention  trials  indicate  that  consumption  of  natural 
astaxanthin could contribute to prevention of atherosclerosis. Iwamoto et al. [226] reported a dose 
response relationship between astaxanthin and LDL oxidation time, while Yoshida and colleagues 
[227] recently demonstrated that astaxanthin intake ameliorates triglyceride and HDL cholesterol in 
correlation  with  increased  adiponectin.  Antihypertensive  effects  were  also  revealed  when  oral 
administration of astaxanthin for 14 days induced a significant reduction in arterial blood pressure in 
spontaneously hypertensive rats [228]. Furthermore, in a follow-up study, the authors suggest that 
astaxanthin could modulate the oxidative condition and may improve vascular elastin and arterial wall 
thickness in hypertension [229]. 
As diet is now recognised as an important modifiable risk factor for CVD, the incorporation of 
marine bioactives in food could benefit heart health by modifying blood levels of HDL and LDL 
cholesterol, as well as reducing hypertension (Figure 1). In particular, n-3 PUFAs and astaxanthin have 
use as dietary supplements for the prevention or the alleviation of certain CVD as they also reduce 
inflammation often associated with the development of CHD. Besides, several comprehensive reviews 
examine  the  literature  on  pharmacological  studies  of  marine  natural  compounds  that  affect  the 
cardiovascular system [145,230,231]. 
Figure 1. Beneficial effects of marine bioactives on the human cardiovascular system. 
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3.3. Inflammatory Conditions 
Inflammation  is  a  normal  protective  response  to  tissue  damage  or  infection.  However,  if  the 
response is exaggerated, misdirected or long term, inflammation can adversely affect health and give 
rise to many conditions such as inflammatory bowel disease, arthritis and asthma [22,86]. Interestingly 
however,  owing  to  the  involvement  of  inflammatory  mediators  called  eicosanoids,  a  number  of 
inflammatory conditions could potentially be alleviated by dietary modification [22]. 
As  well  as  the  various  benefits  accrued  from  the  consumption  of  n-3  PUFAs  as  discussed 
previously, the eicosanoids derived from n-3 fatty acids are considered to be less inflammatory or even 
anti-inflammatory compared to eicosanoids derived from n-6 fatty acids [20]. Research has shown that 
increasing the balance of n-3 fatty acids in the diet, and consequently favouring the production of EPA 
in the body, or by increasing the dietary intake of EPA and DHA through consumption, leads the body 
to a more anti-inflammatory environment [232]. As a result, the incidence or severity of many chronic 
inflammatory  diseases  may  be  reduced  [20,22,233].  In  Crohn’s  disease  (a  chronic  inflammatory 
disease of the alimentary tract) for example, relapse rates reduced substantially over a 12 month period 
in patients receiving a fish oil supplement [234]. 
Another  anti-inflammatory  compound  found  extensively  in  the  marine  environment  is  the 
carotenoid astaxanthin. The antioxidative properties of astaxanthin are believed to be linked to its 
ability to relieve inflammation [89,224]. Bennedsen et al. [235] found that treatment with a cell extract 
from  the  microalgae  Haematococcus  pluvialis  containing  astaxanthin  reduced  bacterial  load  and 
gastric inflammation in Helicobacter pylori infected mice. It has also been reported that astaxanthin 
significantly  reduces the production of pro-inflammatory  mediators and cytokines,  namely nuclear 
factor-κB  (NF-κB),  tumour  necrosis  factor-α  (TNF-α)  and  interleukin-6  (IL-6)  [236,237],  and 
suppresses T lymphocyte activation in asthma patients [238]. However, further studies are needed to 
fully elucidate the anti-inflammatory effects of astaxanthin. 
3.3.1. Arthritis 
Arthritis describes a condition involving inflammation of the joints and is a disease affecting mostly 
the aged population. Preventing inflammation with its associated pain and reduced mobility symptoms 
is  a  primary  requirement  in  arthritis  treatment  [194].  Due  to  the  involvement  of  inflammatory 
eicosanoids in the aetiology of this disorder, diet may be a potential therapeutic agent [22], and so the 
importance of dietary PUFAs in the treatment of arthritis has been greatly investigated [239–241]. 
Meta-analysis of 17 randomised, controlled trials was conducted by Goldberg and Katz [233] to assess 
the analgesic  effects of  n-3 PUFAs in patients with rheumatoid arthritis or joint pain. Favourable 
outcomes such as reduced patient reported joint pain intensity, minutes of morning stiffness, number of 
painful  and/or  tender  joints  and  reduced  non-steroidal  anti-inflammatory  drugs  consumption  were 
reported following 3 to 4 months supplementation with n-3 PUFAs. In fact, the authors conclude that 
n-3 PUFA supplementation is an attractive adjunctive treatment for joint pain. 
In addition to n-3 PUFAs, clinical investigations suggest that ingestion of collagen hydrolysates, 
which can be isolated from fish waste, reduces pain in patients suffering from osteoarthritis [242]. 
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3.3.2. Asthma 
Fish oil or fish containing more than 2% fat has been found to have a reduced risk of airway 
hyperresponsiveness, and children who regularly eat fresh, oily fresh have a reduced risk of developing 
asthma than children who rarely eat fish [243,244]. Supplementation of diet with n-3 fatty acids also 
confirmed  their  benefit  in  the  reduction  of  breathing  difficulties  and  other  symptoms,  along  with 
reduced drug doses required by asthma patients. During treatment, the increase in the content of n-3 
fatty  acids  in  cell  membranes  was  reported  to  take  place  at  the  expense  of  AA  resulting  in  the 
competitive inhibition of pro-inflammatory eicosanoid production and production of anti-inflammatory 
eicosanoids  [194,245,246].  Moreover,  a  number  of  interventional  studies  have  demonstrated 
improvement in asthmatic status following n-3 PUFA supplementation [247–249]. Emelyanov et al. 
[123] assessed the effect of n-3 PUFA rich lipid extract of New Zealand green lipped mussel on 
symptoms, peak expiratory flow and exhaled hydrogen peroxide (a marker of airway inflammation) in 
patients  with  atopic asthma. This double blind randomised  trial  revealed a significant decrease  in 
daytime  wheeze,  reduction  in  the  concentration  of  exhaled  hydrogen  peroxide  and  an  increase  in 
morning peak expiratory flow compared to the placebo group. 
3.3.3. Neuroinflammation 
Recently,  there  has  been  recognition  of  an  inflammatory  component  to  the  pathology  of 
neurodegeneration, most notably in Alzheimer’s disease but also in Parkinson’s disease and motor 
neuron disease [250]. As anti-inflammatory n-3 PUFAs are preferentially incorporated in the brain, a 
diet rich in EPA and DHA could keep neuroinflammation at a minimum [251]. In fact, elderly people 
who eat fish or seafood, that are highly enriched in n-3 PUFAs, at least once a week, have been shown 
to be at lower risk of developing dementia including Alzheimer’s disease [252,253]. 
Evidence is also emerging which suggests that marine algae could possess therapeutic activities for 
combating neurodegenerative diseases associated with neuroinflammation. Jin and colleagues [254] 
found  that  Ulva  conglobata  extract  almost  completely  suppressed  the  expression  of  the  
pro-inflammatory enzyme cyclooxygenase-2 (COX-2) and inducible nitric oxide (iNOS) in murine 
BV2 microglia. Similarly, the brown alga, Ecklonia cava, was reported to induce significant inhibition 
of NF-κB dependent cytokines as well as iNOS and COX-2, thus reducing inflammation [255]. In 
addition,  red  alga  Neorhodomela  aculeate  could  be  considered  as  a  potential  neuroprotective  and  
anti-inflammatory agent to treat aging related neurological disorders [256]. However, as highlighted by 
the authors, further studies are needed to determine which components of each of the algae contribute 
to the observed anti-inflammatory activities. 
As  well  as  the  nutritional  bioactives  discussed,  numerous  anti-inflammatory  compounds  with 
potential  pharmacological  applications  have  been  isolated  from  marine  sources 
[7,145,230,231,257,258].  Nevertheless,  n-3  PUFAs  appear  to  be  the  most  prominent  and  most 
promising anti-inflammatory agents. In spite of this, there have not been sufficient studies to warrant a 
dietary  recommendation  regarding  the  use  of  n-3  PUFAs  in  the  management  of  inflammatory 
conditions, and so there is a need for more carefully designed and controlled clinical trials in the 
therapeutic applications of n-3 fatty acids [22]. There is, however, a potential complementary role Mar. Drugs 2011, 9                        
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between  drug  therapy  and  a diet rich in  n-3 PUFAs.  An increased  intake of  n-3 fatty  acids  may 
increase the efficacy of anti-inflammatory medications, and perhaps reduce the need for conventional 
drugs. This dietary choice could be achieved through the use of marine-sourced PUFAs as fortificants 
in  margarine,  dairy  products  (milk,  yoghurt,  cheese),  breads  and  baked  goods,  meat-based  and  
fish-based meals, for example. 
3.4. Cognitive Decline and Depression 
Cognitive impairment and dementia are frequent disorders among elderly persons and influence the 
individual’s ability to function independently. Due to the aging of the population, the prevalence of 
cognitive  impairment  and  dementia  are  expected  to  increase  [259].  Drugs  currently  used  in  the 
treatment of cognitive decline and dementia have a very limited therapeutic value, suggesting the 
necessity to potentially individualise new strategies able to prevent and to slow down the progression 
of predementia and dementia syndromes [260]. Numerous epidemiological studies on the association 
between  diet  and  cognitive  decline  suggest  a  role  of  fatty  acids  intake  in  maintaining  adequate 
cognitive  functioning  and  possibly  in  preventing  or  delaying  the  onset  of  dementia,  both  of 
degenerative or vascular origin [261–263]. In particular, fatty fish and marine n-3 PUFA consumption 
was associated with a reduced risk [264]. Moreover, a diet enriched with the algae, Chlorella, reduced 
oxidative  stress  and  significantly  prevented  the  decline  of  cognitive  ability  in  an  age  dependent 
dementia mouse model. The authors suggest that the prolonged consumption of Chlorella has the 
potential to prevent the progression of cognitive impairment [265]. 
Several  hypotheses  could  explain  the  association  between  dietary  unsaturated  fatty  acids  and 
cognitive functioning, including mechanisms through the co-presence of antioxidant compounds in 
food groups rich in fatty acids, via atherosclerosis and thrombosis, inflammation, accumulation of 
amyloid  β-peptide, or  via  an  effect  in maintaining the structural integrity of  neuronal membranes 
[260]. It is also believed that DHA is of particular importance for brain function as it maintains an 
optimal state of neural membranes, enabling membrane fluidity and thickness, which in turn affects 
cell signalling [266,267]. 
In general, PUFAs of marine origin appear to be suitable candidates for functional food ingredients 
to relieve memory deficits associated with aging. Promising results have already been reported in 
young population samples. Supplementation with a fish-flour bread spread containing n-3 PUFAs, 
embedded in a natural food matrix, had a beneficial effect on learning and memory of children [267]. 
In  addition,  a  study  involving  marine  collagen  peptide  (MCP)  derived  from  Chum  Salmon  skin 
demonstrated that MCP facilitates learning and memory in aged mice by reducing oxidative damage in 
the brain and increasing brain derived neurotrophic factor and PSD95 protein expression [268]. 
Several epidemiological- and dietary-based studies also suggest that the consumption of n-3 fatty 
acids is inversely correlated to the prevalence and severity of depression, while clinical studies have 
presented evidence relating to the benefits of n-3 compounds in the treatment of depressive disorders 
[269,270]. In some trials, supplementation with long chain n-3 PUFAs has been shown to improve 
mood in patients with major depression and bipolar disorder [271–274]. More recently, Venna et al. 
[275] revealed that chronic supplementation with n-3 PUFAs induced antidepressant-like effects in Mar. Drugs 2011, 9                        
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mice, while in a similar mouse study, natural products isolated from marine sponges were found to 
possess antidepressant properties[276]. 
3.5. Diabetes 
Dietary  management  of  diabetes  involves  maintaining  both  blood  glucose  and  blood  lipid 
concentrations at as near normal levels as possible to reduce the possibility of associated complications 
developing, e.g., CVD, diabetic neuropathy, retinopathy and nephropathy [22]. As well as offering 
protection  against  heart  disease  and  cancer,  some  marine  extracts  have  been  associated  with 
improvements in glycaemic control (outlined in Table 3). Consequently, these compounds could be 
exploited as potential functional food ingredients in an effort to prevent or diminish insulin resistance 
and diabetes. 
4. Conclusions 
With increased life expectancy, our diet will play a key role in sustaining human health. This is a 
challenge for the food industry as consumers not only demand tasty and convenient food, but also 
healthy, nutritious food [116]. Marine nutraceuticals are both a coherent and attractive option for the 
food industry as there are a multitude of functional food ingredients that can be derived from marine 
sources. It is also believed that, as people become increasingly aware of the association between diet 
and  good health,  the consumption  of  fishery  products will most  likely  increase [8]. Moreover,  in 
relation to marine algae, their content in proteins, carbohydrates, lipids, fibre, metabolites, etc. can be 
influenced  by  their  growing  parameters  (water  temperature,  salinity,  light  and  nutrients)  [5].  This 
means that, from a biotechnological perspective, algae can be considered as natural bioreactors, able to 
provide different types of compounds at different quantities—an appealing attribute to the functional 
food industry. 
Despite the vast possibilities for use of marine bioactives in food, more multidisciplinary research is 
needed.  All  aspects,  including  chemical  composition,  biotechnology,  extraction,  bioactivity,  and 
toxicity should be considered. Also, to effectively transfer the research into a practical field in which 
marine  bioactives  can  be  used  as  functional  food  ingredients,  the  exact  functional  activity  of  the 
extracts/compounds  should  be  determined  [52].  This  primary  objective  should  be  based  on 
investigations in vitro or ex vivo in cellular lines or culture tissues, later in animal models and then 
corroborated  in  studies  of  observation  or  intervention  in  human  clinical  trials  [5].  Finally,  to  be 
employed as ingredients in food products, different studies should be carried out to determine if their 
activity is maintained after manufacturing and cooking processes [52]. 
In  conclusion,  marine  bioactives  appear  to  fit  the  criteria  for  development  as  functional  food 
ingredients. Firstly, they are widely available, with a guaranteed supply. Secondly, marine bioactives 
are naturally occurring compounds, and their isolation/extraction is relatively cost effective. Lastly, 
and probably most importantly, they are functional—their biological activities affect the pathogenesis 
of several diseases. Consequently, ongoing efforts should be made into the research and development 
of marine functional foods with prospect that, in the future, their consumption could lead to a reduction 
in the prevalence and severity of chronic diseases. 
 Mar. Drugs 2011, 9                        
 
 
1081 
Table 3. Antidiabetic properties of marine natural products with established mechanisms of action. 
Compound  Source  Experimental model  Effect/Mechanism of action  Reference 
α-galactosylceramide  Agelas mauritianus sponge  Non-obese diabetic mice  Suppression of IFN-γ, increase of serum Ig E 
levels, and promotion of islet autoantigen specific 
Th2 cells 
Suppression of T- and B-cell autoimmunity to 
islet beta cells 
[277,278] 
Aqueous extracts  Xetospongia muta sponge, 
Bunodosoma granulifera and 
Bartholomea annulata sea 
anemones 
In vitro models  Inhibition of dipeptidyl peptidase IV activity  [279] 
Ethanolic extract  Ulva rigida alga  Wistar diabetic rats  Decreased blood glucose concentrations  [137] 
Extract  Posidonia oceanica phanerogam  Wistar diabetic rats  Decreased blood glucose concentrations  [280] 
Fucosterol  Pelvetia siliquosa alga  Sprague-Dawley 
diabetic rats 
Reduction in serum glucose concentration and 
inhibition of sorbitol accumulation in the lenses 
[281] 
Marine collagen 
peptides 
Wild fish  Human diabetic subjects  Decreased free fatty acids, cytochrome P450 and 
hs-CRP 
Regulation on metabolic nuclear receptors 
[117] 
Methanolic extract  Ecklonia cava alga  Sprague-Dawley 
diabetic rats 
Reduction in plasma glucose levels and increased 
insulin concentration 
Activation of AMPK/ACC and PI3/Akt signalling 
pathways 
[138] 
Microalgal extracts  Chlorella sp. alga, Nitzschia 
laevis diatom 
In vitro models  Inhibition of advanced glycation endproducts 
(AGEs) formation 
[135] 
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Table 3. Cont. 
n-3 PUFAs  Fish oil  Wistar rats  Restoration of insulin receptor and insulin 
receptor substrate-1 tyrosine phosphorylation 
Maintenance of phosphatidylinositol-3’ kinase 
activity and GLUT-4 content in muscle 
[282] 
  Fish oil  Healthy human subjects  Reduction in glucose oxidation, increased fat 
oxidation and glycogen storage 
[283] 
Phenylmethylene 
hydantoins 
Hemimycale arabica sponge  In vitro model 
Sprague-Dawley rats 
Inhibition of glycogen synthase kinase-3β activity 
Increased liver glycogen 
[284] 
Phlorotannin 
components 
Ascophyllum nodosum alga  In vitro models  Inhibition of α-amylase and α-glucosidase 
activities 
[136] 
Sodium alginate  Laminaria angustata alga  Wistar rats  Inhibition of rising blood glucose and insulin 
levels 
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